Monogram Technologies and Zimmer Biomet Extend Antitrust Review Period for Merger, Expected to Complete in Late 2025
Monogram Technologies Inc. has provided an update on its pending merger with Zimmer Biomet Holdings, Inc. The company announced that Zimmer Biomet, in agreement with Monogram, voluntarily withdrew and subsequently resubmitted its pre-merger Notification and Report Form to allow the Federal Trade Commission additional time for review. This move is part of the ongoing cooperation with regulatory authorities to facilitate the merger process. The new 30-day waiting period began on September 4, 2025, and is expected to conclude on October 6, 2025. Monogram and Zimmer Biomet remain committed to completing the merger in the second half of 2025, contingent on receiving necessary regulatory approvals and fulfilling other standard conditions.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monogram Technologies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-087631), on September 05, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。